Paper · 29848605

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK and 34 others. Cancer Discov, 2018. Cited by 215 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Papers, record 29848605. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29848605

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.; PubMed
Journal: Cancer Discov; PubMed
Year: 2018; PubMed
Publication types: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/29848605/; PubMed
DOI: https://doi.org/10.1158/2159-8290.cd-18-0229; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6716598/; PubMed
The journal: https://conductscience.org/library/journal-index/101561693; PubMed
Citations, by iCite: 215; iCite
Relative citation ratio, by iCite: 6.93; iCite
Revised in PubMed: 2020-09-23; PubMed

Authors35

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Pal SK	Sumanta K
2	Rosenberg JE	Jonathan E
3	Hoffman-Censits JH	Jean H
4	Berger R	Raanan
5	Quinn DI	David I	https://orcid.org/0000-0002-1411-0417
6	Galsky MD	Matthew D
7	Wolf J	Juergen
8	Dittrich C	Christian
9	Keam B	Bhumsuk
10	Delord JP	Jean-Pierre	https://orcid.org/0000-0001-7305-5561

1 to 10 of 35Source PubMed

See all 35 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Mutation	Major topic
Phenylurea Compounds	Major topic
Pyrimidines	Major topic
Receptor, Fibroblast Growth Factor, Type 3	Major topic
Urologic Neoplasms	Major topic
Administration, Oral
Aged
Antineoplastic Agents
Female
Humans
Male
Middle Aged
Receptor, Fibroblast Growth Factor, Type 1
Treatment Outcome

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed and NIH

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	11,001,674	Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.	J Clin Oncol	2000	https://conductscience.org/library/papers/11001674	PubMed
2	11,125,122	dbSNP: the NCBI database of genetic variation.	Nucleic Acids Res	2001	https://conductscience.org/library/papers/11125122	PubMed
3	19,561,018	Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads.	Bioinformatics	2009	https://conductscience.org/library/papers/19561018	PubMed
4	20,537,950	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.	Lancet Oncol	2010	https://conductscience.org/library/papers/20537950	PubMed
5	20,644,199	The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.	Genome Res	2010	https://conductscience.org/library/papers/20644199	PubMed
6	21,936,542	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.	J Med Chem	2011	https://conductscience.org/library/papers/21936542	PubMed
7	22,544,022	Absolute quantification of somatic DNA alterations in human cancer.	Nat Biotechnol	2012	https://conductscience.org/library/papers/22544022	PubMed
8	23,002,168	FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.	Cancer Discov	2012	https://conductscience.org/library/papers/23002168	PubMed
9	23,396,013	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.	Nat Biotechnol	2013	https://conductscience.org/library/papers/23396013	PubMed
10	24,142,049	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.	Nat Biotechnol	2013	https://conductscience.org/library/papers/24142049	PubMed

1 to 10 of 30

See all 30 references

Cited by137

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 215 citations.

PMID	Title	Journal	Year	In Papers	Source
42,877,619	Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis.	Front Pharmacol	2026	https://conductscience.org/library/papers/42877619	PubMed
42,870,280	Liquid biopsy in bladder cancer: towards precision oncology.	J Transl Med	2026	https://conductscience.org/library/papers/42870280	PubMed
41,514,604	FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.	Cancers (Basel)	2025	https://conductscience.org/library/papers/41514604	PubMed
41,361,008	Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.	Nat Genet	2026	https://conductscience.org/library/papers/41361008	PubMed
41,310,273	Towards biomarker-driven therapies for urothelial carcinoma.	Nat Rev Clin Oncol	2026	https://conductscience.org/library/papers/41310273	PubMed
41,084,837	Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.	Mol Cancer Ther	2026	https://conductscience.org/library/papers/41084837	PubMed
40,698,358	Liquid Biopsy: Current advancements in clinical practice for bladder cancer.	J Liq Biopsy	2025	https://conductscience.org/library/papers/40698358	PubMed
40,563,862	BMP-2-Driven Osteogenesis: A Comparative Analysis of Porcine BMSCs and ASCs and the Role of TGF-β and FGF Signaling.	Biology (Basel)	2025	https://conductscience.org/library/papers/40563862	PubMed
40,458,574	Deciphering riddles in molecular subtyping of bladder cancer.	Asian J Urol	2025	https://conductscience.org/library/papers/40458574	PubMed
40,234,713	Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.	Nat Rev Urol	2025	https://conductscience.org/library/papers/40234713	PubMed

1 to 10 of 137

See all 137 cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
CDKN2A	1,029	PubTator's text mining	https://conductscience.org/library/genes/1029	NCBI Gene
CDKN2B	1,030	PubTator's text mining	https://conductscience.org/library/genes/1030	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
FGFR2	2,263	PubTator's text mining	https://conductscience.org/library/genes/2263	NCBI Gene
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene
KDM6A	7,403	PubTator's text mining	https://conductscience.org/library/genes/7403	NCBI Gene
MAP2K7	5,609	PubTator's text mining	https://conductscience.org/library/genes/5609	NCBI Gene
MTOR	2,475	PubTator's text mining	https://conductscience.org/library/genes/2475	NCBI Gene
PDCD1	5,133	PubTator's text mining	https://conductscience.org/library/genes/5133	NCBI Gene

1 to 10 of 14

See all 14 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29848605

GET https://conductscience.org/api/papers/v1/29848605/authors?page=2

API reference For AI assistants